CA2263042A1 - Traitement de l'oedeme - Google Patents

Traitement de l'oedeme Download PDF

Info

Publication number: CA2263042A1
Authority: CA; Canada
Prior art keywords: hydrogen; 3alkyl; group; formula; residue
Prior art date: 1999-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2263042

Other languages

English (en)

Inventor

Robert W.A. Kuijpers

Seerp Baarsma

Martin P. Van Hagen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-25

Filing date

1999-02-25

Publication date

2000-08-25

1999-02-25 Application filed by Individual filed Critical Individual

1999-02-25 Priority to CA 2263042 priority Critical patent/CA2263042A1/fr

2000-08-25 Publication of CA2263042A1 publication Critical patent/CA2263042A1/fr

Status Abandoned legal-status Critical Current

Links

206010030113 Oedema Diseases 0.000 title abstract description 6
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims abstract description 22
229940075620 somatostatin analogue Drugs 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 15
208000022873 Ocular disease Diseases 0.000 claims abstract description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 23
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 10
108010016076 Octreotide Proteins 0.000 claims description 10
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
150000002431 hydrogen Chemical group 0.000 claims description 9
229960002700 octreotide Drugs 0.000 claims description 9
108010056088 Somatostatin Proteins 0.000 claims description 8
150000001875 compounds Chemical class 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical group 0.000 claims description 6
102000005157 Somatostatin Human genes 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
206010029113 Neovascularisation Diseases 0.000 claims description 3
125000000539 amino acid group Chemical group 0.000 claims description 3
239000003889 eye drop Substances 0.000 claims description 3
239000012530 fluid Substances 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
UWPXWOJLMYFRGY-VKHMYHEASA-N (2s)-2-(difluoroamino)-2,3,3-trifluoropropanoic acid Chemical compound OC(=O)[C@](F)(C(F)F)N(F)F UWPXWOJLMYFRGY-VKHMYHEASA-N 0.000 claims description 2
CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 2
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 2
-1 C1-11alkyl Chemical group 0.000 claims description 2
150000008574 D-amino acids Chemical class 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
229940012356 eye drops Drugs 0.000 claims description 2
230000037427 ion transport Effects 0.000 claims description 2
229960002437 lanreotide Drugs 0.000 claims description 2
108010021336 lanreotide Proteins 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
210000003583 retinal pigment epithelium Anatomy 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 9
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 3
108010016626 Dipeptides Proteins 0.000 claims 2
IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 claims 1
SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 claims 1
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical group CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 1
239000003885 eye ointment Substances 0.000 claims 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
238000011200 topical administration Methods 0.000 claims 1
229960002730 vapreotide Drugs 0.000 claims 1
108700029852 vapreotide Proteins 0.000 claims 1
230000002207 retinal effect Effects 0.000 abstract description 3
230000004304 visual acuity Effects 0.000 description 9
208000001344 Macular Edema Diseases 0.000 description 6
206010025415 Macular oedema Diseases 0.000 description 5
210000000416 exudates and transudate Anatomy 0.000 description 5
201000010230 macular retinal edema Diseases 0.000 description 5
206010012689 Diabetic retinopathy Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
206010064930 age-related macular degeneration Diseases 0.000 description 4
208000002780 macular degeneration Diseases 0.000 description 4
238000009825 accumulation Methods 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
206010038848 Retinal detachment Diseases 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
230000003902 lesion Effects 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000002301 subretinal fluid Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
206010053781 Anterior chamber cell Diseases 0.000 description 1
206010052127 Anterior chamber flare Diseases 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
208000033379 Chorioretinopathy Diseases 0.000 description 1
241000723353 Chrysanthemum Species 0.000 description 1
235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
208000006992 Color Vision Defects Diseases 0.000 description 1
208000036693 Color-vision disease Diseases 0.000 description 1
206010058202 Cystoid macular oedema Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
OFVXPDXXVSGEPX-UHFFFAOYSA-N Flutoprazepam Chemical compound FC1=CC=CC=C1C(C1=CC(Cl)=CC=C11)=NCC(=O)N1CC1CC1 OFVXPDXXVSGEPX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
201000010206 cystoid macular edema Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000013534 fluorescein angiography Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
229960001494 octreotide acetate Drugs 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2263042 1999-02-25 1999-02-25 Traitement de l'oedeme Abandoned CA2263042A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2263042 CA2263042A1 (fr)	1999-02-25	1999-02-25	Traitement de l'oedeme

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2263042 CA2263042A1 (fr)	1999-02-25	1999-02-25	Traitement de l'oedeme

Publications (1)

Publication Number	Publication Date
CA2263042A1 true CA2263042A1 (fr)	2000-08-25

Family

ID=29555219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2263042 Abandoned CA2263042A1 (fr)	1999-02-25	1999-02-25	Traitement de l'oedeme

Country Status (1)

Country	Link
CA (1)	CA2263042A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1040837A3 (fr) *	1999-02-26	2002-01-02	Erasmus Universiteit Rotterdam	Médicaments pour le traitement des troubles liés à la néovascularisation de lachoroide
WO2002009739A1 (fr) *	2000-07-27	2002-02-07	Novartis Ag	Traitement de troubles oculaires au moyen d'analogues de la somatostatine
AU2010335595B2 (en) *	2009-12-22	2015-08-27	Bcn Peptides, S.A.	Topical ophthalmic peptide formulation

1999
- 1999-02-25 CA CA 2263042 patent/CA2263042A1/fr not_active Abandoned

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1040837A3 (fr) *	1999-02-26	2002-01-02	Erasmus Universiteit Rotterdam	Médicaments pour le traitement des troubles liés à la néovascularisation de lachoroide
WO2002009739A1 (fr) *	2000-07-27	2002-02-07	Novartis Ag	Traitement de troubles oculaires au moyen d'analogues de la somatostatine
AU2010335595B2 (en) *	2009-12-22	2015-08-27	Bcn Peptides, S.A.	Topical ophthalmic peptide formulation
EP2515870B1 (fr) *	2009-12-22	2016-05-25	BCN Peptides, S.A.	Formulation peptidique ophtalmique topique

Legal Events

Date	Code	Title	Description
2002-02-25	FZDE	Dead

Publication	Publication Date	Title
RU2440097C2 (ru)	2012-01-20	Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
AU2002244020B2 (en)	2007-08-16	Methods of treating diabetes mellitus
ZA200406332B (en)	2005-09-28	ACC inhibitors.
AU2002244020A1 (en)	2003-02-27	Methods of treating diabetes mellitus
KR20140105527A (ko)	2014-09-01	강력한 방출-조절된 펩티드 제형
SE503191C2 (sv)	1996-04-15	Farmaceutisk komposition innehållande en somatostatinanalog samt användning därav
HUE030943T2 (en)	2017-06-28	Cyclic somatostatin slow-release formulations
WO1997009060A1 (fr)	1997-03-13	Procede de traitement de la resistance a l'insuline
CN109152776B (zh)	2022-04-29	用于对视网膜神经退行性疾病的局部眼治疗的二肽基肽酶-4抑制剂
AU631547B2 (en)	1992-12-03	Treatment of arthritis
CA2263042A1 (fr)	2000-08-25	Traitement de l'oedeme
AU2022209699A9 (en)	2024-02-08	Intranasal formulations and delivery of somatostatin mimetics and uses thereof
WO2025232124A1 (fr)	2025-11-13	Compositions pharmaceutiques et leurs utilisations, et procédés pour améliorer la stabilité au stockage de compositions pharmaceutiques
WO2002009739A1 (fr)	2002-02-07	Traitement de troubles oculaires au moyen d'analogues de la somatostatine
US20020142944A1 (en)	2002-10-03	Treatment of ocular disorders
EP3601322A1 (fr)	2020-02-05	Mimétiques de la calcitonine pour le traitement de maladies et de troubles
AU2017206624A1 (en)	2018-07-26	Pharmaceutical formulations for the treatment of diabetes
US20250154220A1 (en)	2025-05-15	Insulin analogs for the treatment of human metabolic disorder and disease
GB2239178A (en)	1991-06-26	Somatostatin analogues for the treatment of breast cancer
WO2000062796A1 (fr)	2000-10-26	Agents de traitement des troubles de la fonction pancreatique
Haddock et al.	1991	The effect of the somatostatin analogue SMS 201-995 on experimental pancreatic carcinogenesis in the Syrian golden hamster
US20150018271A1 (en)	2015-01-15	Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
JPS6072824A (ja)	1985-04-24	代謝疾患治療用医薬製剤
Scarpignato	1996	Octreotide, the Synthetic Long-Acting Somatostatin Analogue: Pharmacological
CN118984715A (zh)	2024-11-19	包含新型肽的用于治疗黄斑变性的组合物